About our research group/lab
Bob Löwenberg’s research is concerned with developmental diagnostics and therapeutics, in particular in acute myeloid leukemia (AML) in the context of single center and multicenter prospective clinical trials.
These trials evaluate novel agents and novel therapeutic approaches with account of the molecular heterogeneity of the disease. The large phase II and phase II studies are embedded in the HOVON Cooperative Group Network. Other activities relate to the in depth genomic analysis of banked AML patient specimens, eg with regard to their therapeutic impact and prognostic significance.
Research is conducted in close cooperation with various other colleague investigators at the Dept of Hematology at the Erasmus MC Rotterdam.